February 2024- GSK today announced that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions.
As previously announced, the acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter phase II clinical development for the treatment of adult patients with asthma. AIO-001 could expand GSK’s respiratory biologics portfolio to potentially reach 40% of severe asthma patients with low T2 inflammation (a type of overactive immune response associated with asthma). AIO-001 has the potential to be administered every six months due to its high potency and long half-life, which could redefine the standard of care.
Tony Wood, Chief Scientific Officer, GSK, said: “Given the limited treatment options for asthma patients with low T2 inflammation, we look forward to using our deep respiratory expertise to potentially offer a long-acting biologic to a broader portion of the 315 million patients living with asthma.”
Also Read: New collaboration between Boehringer Ingelheim and Sleip leverages AI technology
GSK has an industry-leading portfolio of marketed and investigational medicines to address a range of respiratory diseases, including biologics aimed at treating the subset of asthma pati....READ MORE
February 2024- GSK today announced that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unme...
A virtual marketplace leading your business into the future
